English

CASI PHARMACEUTICALS, INC.

EDGAR

CASI Report (type unavailable) · filed 2026-09-02

Annual consolidated revenue for 2025: about Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 20.71M, using the latest reported figures. The previous period, 2024, was about Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 28.54M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

20.7 million Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg

2025 · Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg

Exact inputs and evidence

Revenue: 20712000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Source

Operating margin

-217.3%

2025 · %

Exact inputs and evidence

Operating Income: -45007000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Source
Revenue: 20712000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Source

Operating cash flow

-20.8 million Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg

2025 · Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg

Exact inputs and evidence

Operating Cash Flow: -20800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Source

Free cash flow

-20.8 million Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg

2025 · Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg

Exact inputs and evidence

Operating Cash Flow: -20800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Source
Capital Expenditure: 16000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Source

Cash and cash equivalents: 5.6 million Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2025-12-31 Source
Exact value

5600000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg
Long-term debt including current maturities: Not available
Shares outstanding: 20.6 million Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw 2025-12-31 Source
Exact value

20555873 Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw

Reported share-count change

32.68% · 5.06 million Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

15492581 Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw · 2024-12-31· Source
20555873 Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw · 2025-12-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-02.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: 2 of 11 periods available· newest 2025-12-31
Total liabilities: 2 of 11 periods available· newest 2025-12-31
Current assets: 2 of 11 periods available· newest 2025-12-31
Current liabilities: 2 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-27.4%

Prior period

Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 28.54 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 20.71 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

20712000 − 28537000 = -7825000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg

28537000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
20712000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CASI PHARMACEUTICALS, INC. · 2025-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Year-over-year change in Revenue: -7825000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 20712000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#1607649 Filing: 000110465926061632 Input fundies:Revenue: 28537000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#1608663 Filing: 000110465926061632
The citation records this snapshot. The page link may show a newer release later.
Net income
−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 8.8 million

Prior period

−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 39.26 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 48.06 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-48058000 − -39258000 = -8800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg

-39258000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-48058000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CASI PHARMACEUTICALS, INC. · 2025-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Year-over-year change in Net income: -8800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -48058000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2750776 Filing: 000110465926061632 Input fundies:NetIncome: -39258000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2751720 Filing: 000110465926061632
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 8.42 million

Prior period

−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 29.22 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 20.8 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-20800000 − -29224000 = 8424000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg

-29224000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-20800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CASI PHARMACEUTICALS, INC. · 2025-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Year-over-year change in Operating cash flow: 8424000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -20800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2185184 Filing: 000110465926061632 Input fundies:OperatingCashFlow: -29224000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2052560 Filing: 000110465926061632
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-92.8%

Prior period

Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 223,000

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 16,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

16000 − 223000 = -207000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg

223000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
16000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CASI PHARMACEUTICALS, INC. · 2025-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Year-over-year change in Capital expenditure: -207000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 16000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2060392 Filing: 000110465926061632 Input fundies:CapitalExpenditure: 223000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2061458 Filing: 000110465926061632
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 20.71 million 100% of revenue
Operating costs Derived Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 65.72 million 317% of revenue
Operating income −Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 45.01 million −217% of revenue
Tax, interest and other Derived Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 3.05 million 15% of revenue
Net income −Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 48.06 million −232% of revenue

Cash

Operating cash flow −Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 20.8 million −100% of revenue
Capital expenditure Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 16,000 0.1% of revenue
Free cash flow Derived −Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 20.82 million −101% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 Operating loss: operating costs were 174% of revenue.
2024 Operating loss: operating costs were 239% of revenue.
2025 Operating loss: operating costs were 317% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	33879000	58959000 Derived	-25080000	1880000 Derived	-26960000	-20171000 Derived	Source 2023-01-01 – 2023-12-31: 33879000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Revenue Open source 2023-01-01 – 2023-12-31: -25080000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -26960000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Net Income Open source 2023-01-01 – 2023-12-31: -19967000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 204000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	28537000	68158000 Derived	-39621000	-363000 Derived	-39258000	-29447000 Derived	Source 2024-01-01 – 2024-12-31: 28537000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Revenue Open source 2024-01-01 – 2024-12-31: -39621000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -39258000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Net Income Open source 2024-01-01 – 2024-12-31: -29224000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 223000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	20712000	65719000 Derived	-45007000	3051000 Derived	-48058000	-20816000 Derived	Source 2025-01-01 – 2025-12-31: 20712000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Revenue Open source 2025-01-01 – 2025-12-31: -45007000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -48058000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Net Income Open source 2025-01-01 – 2025-12-31: -20800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 16000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Capital Expenditure Open source

Amounts are exact, in Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 20.7M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg)	Source evidence
20232023-12-31	Revenue	33879000	Revenue: 33879000 Open source
20242024-12-31	Revenue	28537000	Revenue: 28537000 Open source
20252025-12-31	Revenue	20712000	Revenue: 20712000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-27.4% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 33879000 Open source
20242024-12-31	Year over year	-15.8%	Revenue: 28537000 Open source Revenue: 33879000 Open source
20252025-12-31	Year over year	-27.4%	Revenue: 20712000 Open source Revenue: 28537000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -217.3% 2025

Net margin -232% 2025

Free cash flow margin -100.5% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	-74%	Operating Income: -25080000 Open source Revenue: 33879000 Open source
20242024-12-31	Operating margin	-138.8%	Operating Income: -39621000 Open source Revenue: 28537000 Open source
20252025-12-31	Operating margin	-217.3%	Operating Income: -45007000 Open source Revenue: 20712000 Open source
20232023-12-31	Net margin	-79.6%	Net Income: -26960000 Open source Revenue: 33879000 Open source
20242024-12-31	Net margin	-137.6%	Net Income: -39258000 Open source Revenue: 28537000 Open source
20252025-12-31	Net margin	-232%	Net Income: -48058000 Open source Revenue: 20712000 Open source
20232023-12-31	Free cash flow margin	-59.5%	Revenue: 33879000 Open source Operating Cash Flow: -19967000 Open source Capital Expenditure: 204000 Open source
20242024-12-31	Free cash flow margin	-103.2%	Revenue: 28537000 Open source Operating Cash Flow: -29224000 Open source Capital Expenditure: 223000 Open source
20252025-12-31	Free cash flow margin	-100.5%	Revenue: 20712000 Open source Operating Cash Flow: -20800000 Open source Capital Expenditure: 16000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg -20.8M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg)	Source evidence
20232023-12-31	Operating cash flow	-19967000	Operating Cash Flow: -19967000 Open source
20242024-12-31	Operating cash flow	-29224000	Operating Cash Flow: -29224000 Open source
20252025-12-31	Operating cash flow	-20800000	Operating Cash Flow: -20800000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg -20.8M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg)	Source evidence
20232023-12-31	Free cash flow	-20171000	Operating Cash Flow: -19967000 Open source Capital Expenditure: 204000 Open source
20242024-12-31	Free cash flow	-29447000	Operating Cash Flow: -29224000 Open source Capital Expenditure: 223000 Open source
20252025-12-31	Free cash flow	-20816000	Operating Cash Flow: -20800000 Open source Capital Expenditure: 16000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

245.3% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Liabilities / assets	Not reported	No source recorded
20242024-12-31	Liabilities / assets	96.6%	Total Liabilities: 51823000 Open source Total Assets: 53674000 Open source
20252025-12-31	Liabilities / assets	245.3%	Total Liabilities: 62932000 Open source Total Assets: 25650000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.27× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
20242024-12-31	Current assets / current liabilities	1.09×	Current Assets: 39576000 Open source Current Liabilities: 36452000 Open source
20252025-12-31	Current assets / current liabilities	0.27×	Current Assets: 13457000 Open source Current Liabilities: 49670000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 26.96 million Exact value Exact value: -26960000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2023-01-01 – 2023-12-31: -26960000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Net Income Open source Share or cite Citation for Net Income · CASI PHARMACEUTICALS, INC. · 2023-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Net Income: -26960000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg&dimensions= Input fundies:NetIncome: -26960000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2752664 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 19.97 million Exact value Exact value: -19967000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2023-01-01 – 2023-12-31: -19967000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CASI PHARMACEUTICALS, INC. · 2023-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Operating Cash Flow: -19967000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg&dimensions= Input fundies:OperatingCashFlow: -19967000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2053662 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 204,000 Exact value Exact value: 204000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2023-01-01 – 2023-12-31: 204000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CASI PHARMACEUTICALS, INC. · 2023-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Capital Expenditure: 204000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg&dimensions= Input fundies:CapitalExpenditure: 204000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2062491 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 20.17 million Calculation and evidence -19967000 − 204000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Exact free cash flow: -20171000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2023-01-01 – 2023-12-31: -19967000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 204000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CASI PHARMACEUTICALS, INC. · 2023-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Free cash flow: -20171000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19967000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2053662 Filing: 000110465926061632 Input fundies:CapitalExpenditure: 204000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2062491 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 39.26 million Exact value Exact value: -39258000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2024-01-01 – 2024-12-31: -39258000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Net Income Open source Share or cite Citation for Net Income · CASI PHARMACEUTICALS, INC. · 2024-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Net Income: -39258000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg&dimensions= Input fundies:NetIncome: -39258000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2751720 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 29.22 million Exact value Exact value: -29224000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2024-01-01 – 2024-12-31: -29224000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CASI PHARMACEUTICALS, INC. · 2024-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Operating Cash Flow: -29224000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg&dimensions= Input fundies:OperatingCashFlow: -29224000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2052560 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 223,000 Exact value Exact value: 223000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2024-01-01 – 2024-12-31: 223000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CASI PHARMACEUTICALS, INC. · 2024-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Capital Expenditure: 223000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg&dimensions= Input fundies:CapitalExpenditure: 223000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2061458 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 29.45 million Calculation and evidence -29224000 − 223000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Exact free cash flow: -29447000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2024-01-01 – 2024-12-31: -29224000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 223000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CASI PHARMACEUTICALS, INC. · 2024-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Free cash flow: -29447000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29224000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2052560 Filing: 000110465926061632 Input fundies:CapitalExpenditure: 223000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2061458 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 48.06 million Exact value Exact value: -48058000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2025-01-01 – 2025-12-31: -48058000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Net Income Open source Share or cite Citation for Net Income · CASI PHARMACEUTICALS, INC. · 2025-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Net Income: -48058000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg&dimensions= Input fundies:NetIncome: -48058000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2750776 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 20.8 million Exact value Exact value: -20800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2025-01-01 – 2025-12-31: -20800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CASI PHARMACEUTICALS, INC. · 2025-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Operating Cash Flow: -20800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg&dimensions= Input fundies:OperatingCashFlow: -20800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2185184 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 16,000 Exact value Exact value: 16000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2025-01-01 – 2025-12-31: 16000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CASI PHARMACEUTICALS, INC. · 2025-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Capital Expenditure: 16000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg&dimensions= Input fundies:CapitalExpenditure: 16000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2060392 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 20.82 million Calculation and evidence -20800000 − 16000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Exact free cash flow: -20816000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg 2025-01-01 – 2025-12-31: -20800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 16000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CASI PHARMACEUTICALS, INC. · 2025-12-31 CASI PHARMACEUTICALS, INC. (edgar:1962738) Free cash flow: -20816000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1962738?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20800000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2185184 Filing: 000110465926061632 Input fundies:CapitalExpenditure: 16000 Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm#2060392 Filing: 000110465926061632 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

69 filings · 651 latest values · 651 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001962738, 1962738, CASI, casif, edgar:1962738

Also known as CASI PHARMACEUTICALS, INC., CASI Pharmaceuticals Holdings, Inc., CASI Pharmaceuticals, Inc.

CASI PHARMACEUTICALS, INC.

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation